3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
6
Terminated
3
Unknown
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
6
Leukemia, Myeloid, Acute
4
Thyroid Neoplasms
2
Neoplasms
2
Hepatoblastoma
2
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Melanoma
1
Gastrointestinal Stromal Tumors
1
Fibrolamellar hepatocellular carcinoma
1
Desmoplastic Small Round Cell Tumor
1
Carcinoma
1
Interventions
Cisplatin
10
pembrolizumab
8
Carboplatin
8
Paclitaxel
6
durvalumab
5
Pemetrexed
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
osimertinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Taxes
3
Nivolumab
3
Gemcitabine
3
Docetaxel
3
Bevacizumab
3
cabozantinib
2
atezolizumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Radiation
2
Platinum
2
Immunoglobulin G
2
Disulfides
2
CP protocol
2
Biopsy
2
1,2-diaminocyclohexaneplatinum II citrate
2
trifluridine tipiracil drug combination
1
tremelimumab
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma
×
Sorafenib
×
Clear all
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts